A new study published in Frontiers in Immunology reveals how the measurement of serum IL-12/IL-23 at week 8 of treatment with ustekinumab can be an early predictor of the response in Crohn’s disease. This study potentially guiding personalised treatment strategies and ultimately long-term response.